A Phase II Trial of Prostaglandin E2 Inhibition Using Meloxicam Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
Conditions: Lymphoma | Multiple Myeloma
Age: Between 18 - 100 Years
Gender: Male or Female
histologic diagnosis of multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL)
eligible to undergo autologous PBSC transplantation on institutional protocols
adequate organ function
no prior attempt at mobilizing PBSC
at least 4 weeks from last cytotoxic chemotherapy or immunomodulatory drugs
at least 2 weeks from last treatment with a proteasome inhibitor
must be negative for HIV
have received radiation therapy within the past 4 weeks
have active central nervous system involvement
prior autologous, syngeneic or allogeneic hematopoietic stem cell transplant
ave received prior bone seeking radionuclides
have received myeloid growth factors within 2 weeks before mobilization attempt on this study
have taken nonsteroidal antiinflammatory drugs (NSAID) in the past 14 days before treatment on this protocol
have nor had active or recent peptic ulcer disease within the past 6 months
patients with a history of asthma will be excluded because of the potential for NSAID to precipitate asthma in these patients.
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required